posted
52 week low .004, trading at .0055. When it bounced off that .004 in July it went to .0087. Possible double if it slips a little lower.
Posts: 4893 | From: Burbank IL USA | Registered: Feb 2004
| IP: Logged |
posted
Chart shows we made it to the 200 DMA you know what that means!http://stockcharts.com/def/servlet/SC.web?c=htds,uu[m,a]daclyyay[pb50!b200][vc60][iUb14!La12,26,9]&a...
Posts: 2322 | From: FL | Registered: Aug 2004
| IP: Logged |
posted
Hard to Treat Diseases, Incorporated Files U.S. Provisional Patent Application
December 17, 2004 08:00:00 (ET)
DELRAY BEACH, Fla., Dec 17, 2004 (BUSINESS WIRE) -- Hard to Treat Diseases, Incorporated (HTTD) (Pink Sheets: HTDS) Announces Filing of U.S. Provisional Application for Methods and Compositions for Treatment of Viral Infections.
HTTD is no longer a "one-drug company" that is reliant solely on the promotion of Tubercin(R).
The provisional application discloses the testing results of HTTD's proprietary formulation for the treatment of viral infections, which was recently filed on behalf of HTTD as a result of ongoing testing and research conducted on various compounds and substances that HTTD owns, controls or has the licensed rights to. Testing results could not be released until the provisional application was filed due to the confidential and sensitive nature of the information. Recently, the major focus of HTTD, its research team and patent attorneys has been on preparing and filing the provisional application.
Testing results to date have been finalized and incorporated in the provisional application. An overview of the results will be released in the very near future. The testing documents comprise a valuable asset that has been created for HTTD. This asset, along with the underlying testing documents, is confidential, not available to competitors, and HTTD has taken extraordinary steps to maintain its confidential nature and contents.
HTTD is no longer a "one-drug company" that is reliant solely on the promotion of Tubercin(R). In addition to our proprietary formulation and various compounds, referenced in the provisional application, HTTD also acquired and holds the worldwide (except Korea) marketing rights and license to manufacture, use, market, distribute and otherwise to commercialize Tubercin(R), which includes Tubercin(R)'s issued patents in the following countries:
Japanese patent: issued 6/12/98 United States patent: issued 8/14/01 European patent: issued 8/13/03 Canada patent: issued 5/11/04
Mr. Colm J. King, CEO of HTTD, commented, "HTTD's value and goals have been strengthened with the provisional application. We will continue to aggressively advance the testing of Tubercin(R) in the U.S.; in addition to aggressively advance the testing of our proprietary formulation and other compounds and substances, contained in the provisional application, in the U.S.; and make strategic decisions with the goal of being involved in negotiations with major drug firms within 18 months."
Mr. King added, "Testing and evaluation results are an essential interim step in obtaining the FDA approval necessary to market a product. Our testing and research has been supervised and conducted in U.S. FDA approved laboratories by experienced medical and scientific professionals. HTTD will vigorously enforce its lawful rights, which includes defending its advantageous business relationships and negotiations that are instrumental in establishing a solid reputation and significant presence in our field and attaining the goals of benefiting patients and HTTD's shareholders."
HTTD is currently involved in litigation regarding the rights to Tubercin(R). Additional information and details regarding the litigation can be viewed on our website at: http://www.htdsotc.com
posted
Hard to Treat Diseases, Incorporated Announces Litigation and Company Update
January 14, 2005 13:02:57 (ET)
DELRAY BEACH, Fla., Jan 14, 2005 (PRIMEZONE via COMTEX) -- Hard to Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that on January 10, 2005, The Federal Court Entered an Order Denying Defendant Shinn Capital Group Inc.'s Motion to Dismiss Plaintiff's Second Amended Complaint for Lack of Personal Jurisdiction and an Omnibus Order on Defendants Shinn and Knights' Counterclaim and Affirmative Defenses.
In the Order Denying Defendant Shinn Capital Group Inc.'s Motion to Dismiss Plaintiff's Second Amended Complaint for Lack of Personal Jurisdiction, the Court denied Shinn Capital Group, Inc.'s Motion to Dismiss Plaintiff, Hard to Treat Diseases, Inc.'s Second Amended Complaint for Lack of Personal Jurisdiction.
In the Omnibus Order, the Court granted HTTD's Motion to Dismiss the Abuse of Process Counterclaim filed by Defendant Shinn. Additionally, the Court struck the following affirmative defenses of Defendant Shinn: lack of consideration; failure of performance and failure to comply with "conditions precedent" in relation to unconsummated contract or Share Exchange Agreement; misrepresentation or fraud; illegality; and unclean hands. The Court denied HTTD's Motion to Strike as to the affirmative defense of qualified privilege.
In the Omnibus Order, the Court granted HTTD's Motion to Dismiss the Abuse of Process Counterclaim filed by Defendant Knight. Additionally, the Court struck the following affirmative defenses of Defendant Knight: lack of consideration and failure of performance; failure to comply with "conditions precedent;" statute of frauds/waiver in relation to unconsummated contract or Share Exchange Agreement; misrepresentation and fraud; illegality and unclean hands. The Court denied HTTD's Motion to Strike as to the affirmative defense of qualified privilege.
As to the affirmative defenses stricken by the Order, Defendants Shinn and Knight have 10 days to file amended defenses.
In the Omnibus Order, the Court denied HTTD's Motion to Strike Defendants' Cross Motion for Summary Judgment.
The Federal Court date for Partial Summary Judgment is set for January 20, 2005.
Pursuant to the Court's October 25, 2004 Order Re-Setting Hearing on Plaintiff's Motion for Summary Judgment, HTTD's Motion for Partial Summary Judgment is set for hearing on January 20, 2005.
On January 10, 2005, the Court denied HTTD's Motion for Entry of Partial Summary by Default for Defendants' failure to file a response within the prescribed deadlines.
The Judge's ruling will be released as soon as we receive it.
We are fully confident in the judiciary and the legal process under which HTTD is proceeding.
HTTD is currently involved in litigation regarding the rights to Tubercin(r). Additional information and details regarding the litigation can be viewed at our website at: http://www.htdsotc.com
Testing Results
Testing results to date have been positive and favorable. The results of this testing are not available to any competitors and HTTD has taken extraordinary steps to maintain the confidential nature of these results and all future results. The testing, and the documents reflecting that testing. are instrumental in HTTD's goal of negotiating and establishing advantageous business relations with major drug firms upon the resolution of the pending litigation. These results will be available to shareholders upon HTTD's discretion due to the confidential nature of the negations into which HTTD is endeavoring to enter as well as the need to maintain the commercially reasonable confidentiality necessary with such intellectual property. HTTD's goal is to maximize the benefit to its shareholders; not to jeopardize the Company's potential value and position by disseminating information that can negatively impact the confidentiality of its products, intellectual property, and possible negotiations.
HTTD's "Corporate Overview" has been revised to reflect the company's current position and strategy. The "Corporate overview" can be viewed on our website at http:// www.htdsotc.com
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
SOURCE: Hard to Treat Diseases, Inc.
Hard to Treat Diseases, Incorporated Colm J. King, CEO (561) 272-6900 www.htdsotc.com
-------------------- It is always darkest before it goes completely BLACK!!! Posts: 2322 | From: FL | Registered: Aug 2004
| IP: Logged |
posted
Hard to Treat Diseases, Incorporated's Motion for Partial Summary Judgment is Under Advisement by Court Wednesday January 26, 8:00 am ET
DELRAY BEACH, Fla., Jan. 26, 2005 (PRIMEZONE) -- Hard to Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announced today that the Federal Court heard oral argument on the Company's Motion for Partial Summary Judgment Against Defendants Shinn and Knight during a hearing held on January 20, 2005.
During the hearing before the Court, HTTD presented a concise overview of the facts and legal arguments, with reference to specific exhibits, to the Court. The Company's position has been consistent throughout this litigation. Defendants have presented three alternative and sometimes inconsistent responses to HTTD's claims. These claims, issues, defenses, and references to facts had been extensively briefed and filed with the Court prior to the hearing. The Federal Court carefully listened to the arguments and points of the Company and Defendants Shinn and Knight and advised the parties that it will review the Parties' briefs before issuing a ruling.
At the close of the hearing, the Court acknowledged that in many business-related disputes it is in the best interests of the parties to seek a negotiated resolution before trial. However, the Court noted that the parties may seek to move towards a trial as soon as practicable.
The Federal Judge's ruling will be posted on HTTD's website at: http://www.htdsotc.com and a press release issued as soon as the ruling is received.
Management's intention and goal with this litigation is to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin (r). Additional information and details regarding the litigation can be viewed at our website at: http://www.htdsotc.comPosts: 2322 | From: FL | Registered: Aug 2004
| IP: Logged |
posted
Hard to Treat Diseases, Incorporated Receives Court's Order Regarding Summary Judgment Thursday January 27, 3:25 pm ET
DELRAY BEACH, Fla., Jan. 27, 2005 (PRIMEZONE) -- Hard to Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) received the Court's Order today Denying Plaintiff's Motion For Summary Judgment & Denying Defendant's Cross Motion For Summary Judgment. A copy of the Court's Order signed January 25, 2005 can be viewed on our website at: http://www.htdsotc.com
It is the Company's understanding that Summary Judgment requires a finding that there are no material issues of genuine fact. Both Defendants, Shinn and Knight, have contested whether the Share Exchange Agreement closed and whether HTTD is entitled to the rights of Tubercin(R).
The Court found that there are factual issues that must be determined in a setting other than a Motion for Summary Judgment because a Summary Judgment is only appropriate for the resolution of issues in which the material issues of genuine fact are undisputed. The Court denied both the Plaintiff's and Defendant's motions.
It is the Company's position that both Shinn and Knight have admitted that they were officers and directors of HTTD because of their statements in court documents, their press releases, their signed Board Minutes, their signed Corporate Resolutions, their representations to the world and numerous correspondence.
It is also the Company's position that both Shinn and Knight have admitted to the consummation, acceptance and closing of the Share Exchange Agreement through their press releases, their signed Board Minutes, their signed Corporate Resolutions, their correspondence, their representations to the world and their signed correspondence to Dr. Chung, the inventor and patent-holder of Tubercin(R).
We are fully confident in the judiciary and the legal process under which HTTD is proceeding.
Management's intention and goal with this litigation is to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin(R). Additional information and details regarding the litigation can be viewed at our website at: http://www.htdsotc.com _________________ If what you did yesterday isn't working, change it!!!!
-------------------- It is always darkest before it goes completely BLACK!!! Posts: 2322 | From: FL | Registered: Aug 2004
| IP: Logged |
posted
Hard to Treat Diseases, Incorporated Announces Litigation Status Update Thursday February 3, 8:00 am ET
DELRAY BEACH, Fla., Feb. 3, 2005 (PRIMEZONE) -- Hard to Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces today a litigation status update relating to its claims against former Company officers and directors Ronald Shinn and Gerry Knight and Shinn Capital Group Inc. ADVERTISEMENT
As previously announced, HTTD filed a Motion for Emergency Preliminary Injunction against Shinn and Knight for their actions relating to ArTec, Inc.'s claims to Tubercin(r). While the motion was pending, on December 23, 2004, the Securities and Exchange Commission issued an order suspending the trading of ArTec. The SEC only has the authority to suspend trading for a 10 day period, however, the SEC also warned broker/dealers that they ``should be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange Act, at the termination of the trading suspension, no quotation may be entered unless and until they have strictly complied with all of the provisions of the rule. ...If any broker or dealer is uncertain as to what is required by Rule 15c2-11, he or she should refrain from entering quotations relating to ATKJ's securities until such time as he or she has familiarized himself or herself with the rule and is certain that all of its provisions have been met. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.'' SEC Release No. 50923.
It is the Company's position that the SEC's suspension of trading in ArTec, along with the additional broker/dealer requirements, has the substantially similar impact as the Preliminary Injunction that had been sought. Management has decided that, as a practicable matter of efficiency and economy, the Motion for Emergency Preliminary Injunction should be withdrawn as it would replicate the efforts of the SEC. If circumstances change, the Company will consider all available options to enforce its legal rights.
HTTD filed a Motion to Compel and Motion for Sanctions against Shinn and Knight for failure to produce documents requested in the course of the litigation. On January 19, 2005, the Court granted HTTD's Motion to Compel, ordering Defendants to produce business records and documents. The Court denied HTTD's Motion for Sanctions, with prejudice for HTTD to refile the Motion for Sanctions along with documents indicating the amount of attorneys' fees and costs associated with filing the Motion to Compel. The documents HTTD has sought relate to the operation of the Company, its records and finances, and other material information.
The Company has been advised that courts routinely encourage the negotiated resolution of litigated matters. As an example, court-ordered mediation is required in the overwhelming majority of civil litigation. Following that advice, the Company has undertaken to seek a negotiated resolution to the current business-related dispute with defendants. This resolution would be in the best interests of the parties and HTTD's shareholders, because it could resolve the dispute more quickly, more economically, and allow the parties to exercise some control in the outcome of the settlement. If an immediate resolution can be reached, further litigation can be avoided and HTTD can implement its previously announced strategy of negotiating with major drug firms.
Management's intention and goal with this litigation is to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders. If negotiations or mediation fail, HTTD is prepared to move towards a trial as soon as practicable, depending on the Court's calendar.
The Company cannot overemphasize the fact that any intent to seek a negotiated resolution does not in any way diminish management's belief and commitment to the strength and validity of its claims against Defendants.
HTTD's shareholders and investors will be kept informed of all developments as they occur regarding the above matters.
HTTD is currently involved in litigation regarding the rights to Tubercin(r). Additional information and details regarding the litigation can be viewed at our website at: http://www.htdsotc.comPosts: 2322 | From: FL | Registered: Aug 2004
| IP: Logged |
posted
Hard to Treat Diseases, Incorporated Announces Share Cancellation and Corporate Restructuring Tuesday February 8, 8:00 am ET
DELRAY BEACH, Fla., Feb. 8, 2005 (PRIMEZONE) -- Hard to Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) (the ``Company'') announces today that it has cancelled 180 million outstanding shares and restructured the Company.
Pursuant to the May 2, 2003 Share Exchange Agreement, the Company issued 350 million shares to Ronald Shinn and his wife, as 100% of the holders of the common stock in Hard to Treat Diseases, Inc. and T-19, both Oklahoma corporations. Once he was an officer and director of the Company, Shinn issued himself an additional 180 million shares without any consideration in return to the Company. HTTD has cancelled the 180 million shares that Shinn issued himself. By canceling these improperly issued shares, the amount of the Company's outstanding stock is decreased by over 20 percent. The 350 million shares issued to Shinn and his wife pursuant to the Share Exchange Agreement will not be cancelled until the litigation with Shinn is resolved.
In conjunction with the extensive discovery conducted in the pending litigation brought by the Company against former officers Shinn and Knight, and as a result of additional information to which the Company is now privy, HTTD has terminated its Consulting Agreement with Harvey Katz.
Harvey Katz is no longer affiliated with HTTD in any capacity other than as a shareholder. Agreements entered into by Mr. Katz, while purporting to act as a consultant for the Company, will be reviewed to ensure that he was acting within the scope of his limited authority.
Additional Company shares may be cancelled in conjunction with or as a result of pending litigation and upon HTTD's determination that shares were issued in error.
The corporate office of HTTD has been relocated to a new location:
New address: 100 East Linton Blvd. Suite 106 B Delray Beach, FL 33483
New telephone No.: 561-278-7856 New facsimile No.: 561-276-2023 Same email: info@htdsotc.com
The $250,000 loan obligation due HTTD, as a result of the sale of recycling assets on May 14, 2004 to International Foam Solutions, Inc. (``IFS''), has been satisfied in full as of January 31, 2005. This satisfaction includes the principal amount of $250,000 and accrued interest in the amount of $7,813. HTTD continues to own 20% of IFS and will benefit from any IFS activity and major transaction entered into by IFS.
Management's intention is not to dilute HTTD's shareholders by issuing unnecessary stock or by performing a reverse split. Stock will be issued only as needed to achieve the Company's goals and, currently, management does not consider that a reverse split is required to achieve HTTD's articulated goal of negotiating and closing a transaction with a major drug firm for the Company's assets.
Management's intention and goal with this litigation is to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD's shareholders and investors will be kept informed of all developments as they occur regarding the above matters.
HTTD is currently involved in litigation regarding the rights to Tubercin(r). Additional information and details regarding the litigation can be viewed at our website at: http://www.htdsotc.comPosts: 2322 | From: FL | Registered: Aug 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
